2 results
Approved WMOPending
Primary: To demonstrate the superior efficacy of Nasalfent in the treatment of BTCP in opioid tolerant subjects who are receiving regular opioid therapy.Secondary: To demonstrate the safety, tolerability, and acceptability of Nasalfent in the…
Approved WMOWill not start
The objective of this post market surveillance registry is to assess whether the Imagio OA/US technology for the indication of breast mass/focal finding diagnosis provides performance characteristics that could be used for worldwide clinical…